Nipro Medical Corp. today announced plans to open its first North American manufacturing facility in Greenville, North Carolina.
The medical device developer said its $398 million project is expected to create 232 jobs over the next five years, including roles in engineering, production, administration and management. The facility will produce devices for diabetes, chronic kidney disease, and other renal health issues.
“This new facility marks a major milestone in Nipro’s commitment to the U.S. market, allowing us to deliver high-quality medical devices that enhance patient outcomes and quality of life across the country,” Nipro Medical Corp. CEO Akira Shimizu said in a news release.
Osaka, Japan-based Nipro is the world’s 36th-largest medical device company, according to Medical Design & Outsourcing‘s 2023 Medtech Big 100 ranking by revenue.
Nipro’s medical segment reported $3.19 billion in revenue for that year’s ranking; that figure increased to $3.23 billion for fiscal 2024. Stay tuned for our 2024 Medtech Big 100 ranking in the coming weeks to see where Nipro lands.
“We are thrilled to start manufacturing our cutting-edge medical devices in the U.S., which will support local healthcare professionals and patients with a stable supply chain and reduced transportation costs,” Tsuyoshi Yamazaki, senior managing director of global business at Nipro, said in the release. “Our close proximity to customers will allow us to better respond to their needs and provide them with timely and effective solutions.”
Nipro said the U.S. facility will “significantly reduce global transportation needs, cutting down on carbon emissions.” The new facility marks what Yamazaki characterized as “a major milestone in our sustainability journey, reflecting our commitment to reducing our carbon footprint.”
Nipro named Krizay Elenitoba-Johnson as VP of manufacturing operations and inaugural site leader.
“I look forward to working with our dedicated team and the supportive community here to achieve great successes,” Elenitoba-Johnson said in the release.
